Search clinical trials for: SAR302503 (TG101348)

Total 12 results

Sanofi

Completed

A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis

Myelofibrosis

United States
Sanofi

Completed

Effect of SAR302503 on ECG Activity in Patients With Solid Tumors

Neoplasm Malignant

Belgium, United States
Sanofi

Completed

Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib (JAKARTA2)

Hematopoietic Neoplasm

United States, Austria, Belgium, Canada, France, Germany, Italy, Netherlands, Spain, United Kingdom
TargeGen

Completed

A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis

Myelofibrosis

United States
Sanofi

Completed

Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal Impairment

Renal Impairment

United States
Sanofi

Completed

Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic Impairment

Hepatic Impairment

United States
Sanofi

Completed

Phase 2 Study of SAR302503 in Patients With Myelofibrosis

Hematopoietic Neoplasm

United States
Sanofi

Completed

Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly

Myelofibrosis

Japan
Sanofi

Completed

Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis (JAKARTA)

Hematopoietic Neoplasm

Austria, Germany, Italy, Spain, United Kingdom, France, Belgium, Israel, Sweden, Australia, United States, Lithuania, Portugal, Korea, Republic of, Singapore, Taiwan, Mexico, Brazil, Canada, Hungary, Ireland, Poland, Romania, Russian... and more
Sanofi

Completed

Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia

Hematopoietic Neoplasm

United States, Spain, France, Canada, Australia, Korea, Republic of, Germany, Italy, United Kingdom
University of Washington

Recruiting

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

Acute Myeloid Leukemia | Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative Neoplasm | Secondary Myelofibrosis | Myeloproliferative Neoplasm, Unclassifiable

United States
Sanofi

Completed

Drug Interaction Study of SAR302503 in Patients With Solid Tumor

Solid Tumor

United States

Search clinical trials for: SAR302503 (TG101348)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Indonesia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations